Stockscreener 앱 받기
143.21
0.55%
-0.78
전일 마감가:
$143.99
열려 있는:
$142.5
하루 거래량:
419.75K
Relative Volume:
0.23
시가총액:
$11.42B
수익:
-
순이익/손실:
$-386.19M
주가수익비율:
-27.25
EPS:
-5.2547
순현금흐름:
$-206.27M
1주 성능:
+7.45%
1개월 성능:
+41.03%
6개월 성능:
+13.21%
1년 성능:
+1,701%
1일 변동 폭
$140.56
$143.61
1주일 범위
$131.86
$147.98
52주 변동 폭
$7.70
$148.83
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
143.10 | 11.54B | 0 | -386.19M | -206.27M | -5.2547 |
VRTX
Vertex Pharmaceuticals Inc
|
520.02 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.50 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.32 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.28 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.90 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | Jefferies | Buy |
| 2026-02-24 | 개시 | Wedbush | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-06 | 개시 | Wolfe Research | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-07-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | Laidlaw | Buy |
| 2024-05-20 | 개시 | BTIG Research | Buy |
| 2024-04-29 | 개시 | Guggenheim | Buy |
| 2024-04-29 | 개시 | Piper Sandler | Overweight |
| 2023-11-14 | 개시 | Leerink Partners | Outperform |
| 2023-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Abivax Adr 주식(ABVX)의 최신 뉴스
Abivax announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewswire Inc.
Why is Abivax stock climbing today? - Investing.com UK
Abivax stock surges on Phase 3 ulcerative colitis data By Investing.com - Investing.com Australia
Abivax Stock Slides as Phase 3 Update Disappoints - TipRanks
2X10 Forecast — Price Target — Prediction for 2027 - TradingView
Abivax SA sponsored ADR (ABVX) loses 41.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Abivax SA Sponsored ADR Actuals & Estimates (NASDAQ:ABVX) - TradingView
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA) - The Globe and Mail
ABVX News | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
Abivax Soars As New Crohn’s Trial Ignites Hopes - TipRanks
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim - The Globe and Mail
Barclays Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Abivax SA Sponsored ADR Stock Is Sinking - TipRanks
Why Abivax Shares Are Sinking Despite Trial Success - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ABIVAX SA-ADR (ABVX) Stock Chart - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Bausch Health Companies (BHC) and Healthequity (HQY) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Leerink Partners Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Why Abivax SA Sponsored ADR Shares Are Sinking - TipRanks
Why This Biotech Plummeted Despite Its 'Best-Case' Study - Investor's Business Daily
Truist cuts Abivax stock price target on malignancy concerns By Investing.com - Investing.com Australia
Abivax shares sink as rare malignancy events cloud strong colitis trial data - Investing.com UK
Why Abivax SA Sponsored ADR Shares Are Sliding - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
What makes Abivax SA sponsored ADR (ABVX) a strong momentum stock: Buy now? - MSN
ABVX Technical Analysis | Trend, Signals & Chart Patterns | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
ABVX Q4 2025 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Biotech ChallengesWeak Earnings Momentum - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and TG Therapeutics (TGTX) - The Globe and Mail
What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Barclays - The Globe and Mail
ABVXAbivax ADR Stock Price and Quote - Finviz
Abivax reports Q1 results, ulcerative colitis trial data - Investing.com
Abivax Shareholders Approve 2025 Accounts and Governance Resolutions at May 11 AGM - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Receives a Buy from Barclays - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Brummer Multi Strategy AB Acquires Shares of 14,375 Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Abivax SA Sponsored ADR $ABVX Shares Acquired by Nan Fung Trinity HK Ltd. - MarketBeat
Abivax Buys Back $90 Million in Royalties via $45 Million ADS Offering, Keeps Cash Runway to Q4 2027 - The Globe and Mail
Number of shareholders of Abivax SA Sponsored ADR – TRADEGATE:2X10 - TradingView
Why Abivax SA Sponsored ADR Shares Are Under Pressure - TipRanks
Abivax Adr (ABVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.85%
자본화:
|
볼륨(24시간):